[1] |
MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin.
Drug traceability coding system in China
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172.
|
[2] |
ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie.
Adverse reaction monitoring of toothpaste in China under the new regulatory system
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222.
|
[3] |
LIU Min, CHEN Yan, LIU Wendong, WANG Haixue.
Updates and reflections on expedited reporting of safety information during drug clinical trials
[J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101.
|
[4] |
TIAN Chunhua, WU Guizhi.
Implementation of periodic benefit risk evaluation reports in China
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384.
|
[5] |
ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang.
Post-marketing active monitoring of medical devices under vigilance
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390.
|
[6] |
PANG Yu, LIU Bo, WU Wenyu, TIAN Yuejie, WANG Tao.
Establishment of patient reporting scheme in the UK and its implications
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1259-1263.
|
[7] |
XIA Xudong, LI Meixia, SUN Yang, YANG Shengya.
Processes of remote inspection of pharmacovigilance for marketing authorization holders
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970.
|
[8] |
ZHANG Qi, CHEN Min, ZHANG Shiqing.
Conditional approval of medical devices in the United States and enlightenment
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1007-1010.
|
[9] |
NIE Xiaolu, TANG Shaowen, YU Jinyang, SONG Haibo, FU Zhu, SUN Feng.
Interpretations of reporting recommendations intended for pharmaceutical risk minimization evaluation studies(RIMES) statement
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(5): 524-529.
|
[10] |
ZHAO Yan, LIU Wenbo, ZHAO Yifei, LI Dong, ZHENG Lijia, SONG Yana, ZHAO Yujuan, DONG Fang.
Applicability of patient registry research to regulation of medical devices
[J]. Chinese Journal of Pharmacovigilance, 2023, 20(4): 423-427.
|
[11] |
CUI Huanhuan, PEI Xiaojing, LI Yanrong, LIU Wendong, WANG Haixue, LAN Gongtao, WANG Tao.
The practice and consideration of pharmacovigilance during clinical trials in China
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1050-1054.
|
[12] |
SHA Mingquan, LI Nannan, XIA Wenjing, WEI Qun, WEN Baoshu.
Research and reflection on regulatory science developments of U.S. FDA
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1055-1059.
|
[13] |
ZHANG Yajuan, JIANG Yang.
Introduction and enlightenment of pharmacovigilance systems in South Korea
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1082-1086.
|
[14] |
ZHAO Yifei, ZHAO Yan, DONG Fang, ZHENG Lijia, LI Dong, SONG Yana.
Introduction and inspiration of international medical device regulators forum patient registry guidelines
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1091-1096.
|
[15] |
BAI Hehe, NIE Xiaojing, XIA Li, MA Li, WANG Jinping, PENG Lirong.
Effect evaluation of adverse drug reactions monitoring based on the Chinese hospital pharmacovigilance system
[J]. Chinese Journal of Pharmacovigilance, 2022, 19(10): 1136-1139.
|